Anita Y. M. Howe, Chaturaka Rodrigo, Evan Brian Cunningham, Mark Douglas, Julia Dietz, Jason Grebely, Stephanie Popping, Javier Alejandro Sfalcin, Milosz Parczewski, Christoph Sarrazin, Adolfo de Salazar, Ana Fuentes, Murat Sayan, Josep Quer, Midori Kjellin, Hege Kileng, Orna Mor, Johan Lennerstrand, Slim Fourati, Velia Chiara Di Maio, Vladimir Chulanov, Jean-Michel Pawlotsky, P. Richard Harrigan, Francesca Ceccherini-Silberstein, Federico Garcia
- Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either ineffective or only partially effective. Multidrug resistance is common in patients for whom DAA treatment fails. Older patients and patients with advanced liver diseases are more likely to select drug-resistant viruses. Collective efforts from international communities and governments are needed to develop an optimal approach to managing drug resistance and preventing the transmission of resistant viruses.
Metadaten| Author: | Anita Y. M. HoweORCiD, Chaturaka RodrigoORCiD, Evan Brian CunninghamORCiD, Mark DouglasORCiD, Julia DietzORCiDGND, Jason GrebelyORCiD, Stephanie Popping, Javier Alejandro Sfalcin, Milosz ParczewskiORCiD, Christoph SarrazinGND, Adolfo de SalazarORCiD, Ana FuentesORCiD, Murat SayanORCiD, Josep QuerORCiD, Midori KjellinORCiD, Hege KilengORCiD, Orna MorORCiD, Johan LennerstrandORCiDGND, Slim Fourati, Velia Chiara Di MaioORCiD, Vladimir ChulanovORCiD, Jean-Michel PawlotskyORCiD, P. Richard Harrigan, Francesca Ceccherini-SilbersteinORCiDGND, Federico GarciaORCiD |
|---|
| URN: | urn:nbn:de:hebis:30:3-631112 |
|---|
| DOI: | https://doi.org/10.1016/j.jhepr.2022.100462 |
|---|
| ISSN: | 2589-5559 |
|---|
| Parent Title (English): | JHEP Reports |
|---|
| Publisher: | Elsevier B.V. |
|---|
| Place of publication: | Amsterdam |
|---|
| Document Type: | Article |
|---|
| Language: | English |
|---|
| Date of Publication (online): | 2022/02/23 |
|---|
| Date of first Publication: | 2022/02/23 |
|---|
| Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
|---|
| Release Date: | 2023/01/09 |
|---|
| Tag: | DAA; HCV; NS5A; RAS; virologic failure |
|---|
| Volume: | 4 |
|---|
| Issue: | 4, art. 100462 |
|---|
| Article Number: | 100462 |
|---|
| Page Number: | 15 |
|---|
| First Page: | 1 |
|---|
| Last Page: | 14 |
|---|
| Note: | Financial support
No financial support was received for the writing of this article. The initial SHARED development was funded in part by Merck and a User Partnership Program grant from Genome British Columbia to P.R.H and A.Y.M.H (UPP029). The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian (or any other) Government. C.R. and J.G. are supported by an NHMRC Investigator Grant (nos. 1173666, 1176131). An NHMRC Program Grant supported RAS testing and data collection by M.W.D. (1053206) and small grants from the Australian Centre for HIV and Hepatitis Virology Research, The University of Sydney, Western Sydney Local Health District Research Education Network, and the Robert W. Storr bequest to the Sydney Medical Foundation (University of Sydney). S.P. received personal fees from Gilead Sciences. Regarding the Italian data, the work was supported in part by the Italian Ministry of Instruction, University and Research (MIUR) (Bandiera InterOmics Protocollo PB05 1°), by the Italian Ministry of Health (RF-2016-02362422), and by Aviralia and Vironet C Foundations. |
|---|
| Institutes: | Medizin |
|---|
| Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
|---|
| Sammlungen: | Universitätspublikationen |
|---|
| Licence (German): |  Creative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International |
|---|
